Dissemination of extreme levels of extracellular vesicles: tissue factor activity in patients with severe COVID-19

Archive ouverte

Guervilly, Christophe | Bonifay, Amandine | Burtey, Stephane | Sabatier, Florence | Cauchois, Raphaël | Abdili, Evelyne | Arnaud, Laurent | Lano, Guillaume | Pietri, Léa | Robert, Thomas | Velier, Mélanie | Papazian, Laurent | Albanese, Jacques | Kaplanski, Gilles | Dignat-George, Françoise | Lacroix, Romaric

Edité par CCSD ; The American Society of Hematology -

International audience. Abstract Coronavirus disease 2019 (COVID-19) has become one of the biggest public health challenges of this century. Severe forms of the disease are associated with a thrombo-inflammatory state that can turn into thrombosis. Because tissue factor (TF) conveyed by extracellular vesicles (EVs) has been implicated in thrombosis, we quantified the EV-TF activity in a cohort of hospitalized patients with COVID-19 (n = 111) and evaluated its link with inflammation, disease severity, and thrombotic events. Patients with severe disease were compared with those who had moderate disease and with patients who had septic shock not related to COVID-19 (n = 218). The EV-TF activity was notably increased in patients with severe COVID-19 compared with that observed in patients with moderate COVID-19 (median, 231 [25th to 75th percentile, 39-761] vs median, 25 [25th to 75th percentile, 12-59] fM; P < .0001); EV-TF was correlated with leukocytes, D-dimer, and inflammation parameters. High EV-TF values were associated with an increased thrombotic risk in multivariable models. Compared with patients who had septic shock, those with COVID-19 were characterized by a distinct coagulopathy profile with significantly higher EV-TF and EV-fibrinolytic activities that were not counterbalanced by an increase in plasminogen activator inhibitor-1 (PAI-1). Thus, this article is the first to describe the dissemination of extreme levels of EV-TF in patients with severe COVID-19, which supports the international recommendations of systematic preventive anticoagulation in hospitalized patients and potential intensification of anticoagulation in patients with severe disease.

Consulter en ligne

Suggestions

Du même auteur

Circulating Endothelial Cells as a Marker of Endothelial Injury in Severe COVID -19

Archive ouverte | Guervilly, Christophe | CCSD

International audience. Beside the commonly described pulmonary expression of the coronavirus disease 2019 (COVID-19), major vascular events have been reported. The objective of this study was to investigate whether...

Caspase-1 activation, IL-1/IL-6 signature and IFNγ-induced chemokines in lungs of COVID-19 patients

Archive ouverte | Cambon, Audrey | CCSD

International audience. Rationale COVID-19-associated acute-respiratory distress syndrome (C-ARDS) results from a direct viral injury associated with host excessive innate immune response mainly affecting the lungs....

Rheopheresis Performed in Hemodialysis Patients Targets Endothelium and Has an Acute Anti-Inflammatory Effect

Archive ouverte | Solignac, Justine | CCSD

International audience. Rheopheresis is a double-filtration plasmapheresis that removes a defined spectrum of high-molecular-weight proteins to lower plasma viscosity and improves microcirculation disorders. This te...

Chargement des enrichissements...